METHOD OF TREATING ULCERATIVE COLITIS
;
treatment of ulcerative proctitis and colitis

colitis foundation of america

 
 
crohn's-and colitis foundation of america

dealing with ulcerative colitis
treatment of colitis ulcerosa
compositions and method
-fo -treatment of ulcerative
colitis
detection and treatment of ulcerative colitis
method of treating ulcerative colitis
method of treating ulcerative colitis with a monoclonal antibody
methods for the treatment of ulcerative colitis
methods of treating established colitis using antibodies
therapeutic agent for ulcerative colitis
therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders
treating a patient with ulcerative colitis
 
methods of treatment for ulcerative colitis using aminosalicylate
therapeutic agent for ulcerative colitis
therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders
treating a patient with ulcerative colitis
 
.

fish oils benefit patients with ulcerative colitis
crohn's disease and ulcerative colitis
!!!!
 

 


A method of treating and/or preventing ulcerative colitis  in humans by daily administering of between 1-6 grams of biological antagonists of Vitamin K generated either in vivo or in vitro by oxidation of tocopherols. 

Ulcerative colitis  is a chronic, inflammatory disease associated with inflammation of the mucosa of the colon, often starting in the distal portion of the colon, and most frequently affecting individuals ranging in age from 14-40. The most common symptoms are bloody diarrhea accompanied by severe cramps and high fever. Hemorrhage, perforation of the colon, and peripheral arthritis are potential complications. At present neither the cause nor an effective non-surgical method of treating the disease are known. Depending on whether the stage of the disease is classified as mild, moderate, moderately severe, or severe, the strategies for treating it differ. For mild attacks treatment is focused on controlling diarrhea usually with diphenoxylate. Moderate and moderately severe forms of the disease are treated with antibiotics, generally sulfasalazine and/or with corticosteroids respectively. Severe attacks of the disease require hospitalization, drug therapy and in extreme situations colectomy if there is massive hemorrhaging or perforation of the colon. The only known cure for severe ulcerative colitis is complete proctocolectomy, but unfortunately, the patient pays a high price as ileostomy is necessary.

While the cause of ulcerative colitis is unknown several lines of evidence suggest that one or more metabolic by-products secreted by bacteria endogenous to the gut may be responsible. The theory that bacteria are involved has its roots in epidemiological studies which have linked colon cancer to ulcerative colitis. For example, work by Greenstein et al in Gastroenterology, Vol. 77, p. 290 (1979), shows that a high percentage of patients that suffer from ulcerative colitis subsequently develop colon cancer. Because of the association of colon cancer and ulcerative colitis it is probable that both diseases are caused by the same or similar bacterial metabolic by-products.

As discussed by Hill in Cancer, Vol. 36, p. 2387 (1975), colon cancer is thought to be due to metabolic conversion of bile acids into carcinogens by bacteria as the bile acids pass through the colon. The link between bile acids and colon cancer is supported by the observation that the risk of developing colon cancer is greater in people that ingest large amounts of fats. Excessive fat, as discussed by Howell in J. Chronic Dis., Vol. 28, p. 67 (1975), stimulates the production and subsequent secretion of bile acids into the gut. The chemical reactions necessary to carry out the conversion of bile acids into potential carcinogens are known, and have been described by Hill in Cancer, Vol. 36, p. 2387 (1975), and Goddard et al in J. Med. Microbiol., Vol. 8, p. 429 (1975). These reactions require an electron acceptor, and as noted by Goddard et al in J. Med. Microbiol., Vol. 8, p. 429 (1975), the likely candidate in the colon is Vitamin K. Thus, it should be possible to prevent both ulcerative colitis and colon cancer by administering to patients drugs that antagonize the effects of Vitamin K.

SUMMARY OF THE INVENTION

According to the present invention a method is described for treating and/or preventing ulcerative colitis involving administering to a patient drugs drawn from a group that are biological antagonists of Vitamin K, particularly derivatives of ?, ?, ?, and ? tocopherol. The drugs are administered in doses of 1-6 grams per day with one third of the dose being taken with each meal. 
 
 
 


There are also herbal medicines which can very effectively treat colitis & ulcerative colitis. Boswellia is an Ayurvedic  (Indian traditional medicine) herb, used as a natural alternative to drugs. Many studies have found that the effectiveness of Boswellia is similar and even superior to sulfasalazine based prescription drugs. (Source Wikipedia: http://en.wikipedia.org/wiki/Ulcerative_colitis. 

We recommend taking a 4 months course of our Boswellia Serrata Extract.
 
 

Order  Boswellia - Shallaki - 4 Months course



  


 

Total of 4 bottles-  of Boswellia - 4 Months course - Taken 2 capusles twice a day.
 
 

U.S.$49/- ONLY.
(All Inclusive) FREE Shipping Worldwide.
 
 

There are NO ADDITIONAL CHARGES. Packing & Shipping is absolutely FREE. We will deliver direct to your door to reach within 12 days from the date of ordering. A signature will be required at the time of delivery. You can give us your daytime work address or Post Box address if no one will be present at home to receive the shipment during daytime. 
 



 

Please use the form below to mail us for any information. We will revert back within 10 hours .


 
Contact us using this form:
Department:
* Name:
* Email:
Company:
Phone:
Message:
A * indicates a field is required


HOME
Boswellia                Colitis                 Sitemap


 
Credit  Card  Processor/online Retailer
RELAXON
1785 O'Brien Road
Columbus, OH-43228
USA
Physical  Shipping  by :
RELAXON 
An  United  States  FDA  Registered  Food  Facility
US  FDA  Registration  Number :    14801626892
USFDA 1993 DSHEA DISCLAIMER : The therapeutic effects of  CYSTONE has not been evaluated by US FDA. CYSTONE  is not intended to diagnose/treat/cure/prevent/mitigate any ailment. Individual results may vary.